

# WAPI's 18th Annual Interdisciplinary CME Conference

1/1/2020

CME OBJECTIVES

Upon completion of this activity, attendees should be able to:

## PERSONALIZING HIV TREATMENT AND PREVENTION IN 2020 - Rena Patel MD ,MPH

1. Recognize currently recommended options for initial HIV treatment regimens.
2. Recognize currently recommended options for HIV prevention; and
3. Drug-drug interactions and other management considerations for a non-HIV specialist.

## THE CURRENT LANDSCAPE FOR VIRAL HEPATITIS AND NON-ALCOHOLIC FATTY LIVER DISEASE IN THE UNITED STATES - Channa Jayasekara MD

1. Discuss the epidemiology of chronic viral hepatitis and non-alcoholic fatty liver disease in the United States, including in specific population sub-groups
2. Correctly interpret viral hepatitis serologies and put serologies into clinical contexts such as a) treatment indicated, b) monitor, c) at risk for disease reactivation, d) prior exposure with viral clearance.
3. Identify current therapeutics for hepatitis B and C and Washington State's effort to eliminate hepatitis C by 2030
4. Describe novel therapeutic targets for hepatitis B and for non-alcoholic fatty liver disease

## TESTICULAR CANCER 101 - Rohan Sharma MD

- Identify current screening recommendations for testicular cancer
- Basic Classification and Treatment recommendations for testicular cancer
- Toxicity and Survivorship Concerns for testicular cancer patients

## PERSONALIZED TREATMENT OF EARLY STAGE BREAST CANCER - Swathi Namburi MD

1. Define the role of chemotherapy in early stage breast cancer.
2. Demonstrate the use of genomic predictors to personalize therapy
3. Describe the personalization of HER2 directed therapy in early stage breast cancer

## WOMEN AND VEINS - Kathy Gibson MD

1. Be able to differentiate between types of contraception and their risks of venous thromboembolic events.
2. Describe the typical presentation of a woman with symptomatic pelvic venous reflux (pelvic congestion syndrome).
3. Outline treatment options for patients with symptomatic varicose veins

#### MSK ULTRASOUND - Atul Gupta MD

1. Define the place for ultrasonography within the spectrum of care for musculoskeletal pathologies.
2. Discuss when to consider regenerative medicine therapies for musculoskeletal pathologies.
3. Describe when to order an MRI versus an ultrasound for musculoskeletal pathologies.

#### SELECTING DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS - Amish J Dave MD

1. Describe the roles of the rheumatologist and primary care provider in diagnosing rheumatoid arthritis
2. Identify the mechanisms of action of biologic and non-biologic disease-modifying anti-rheumatic drugs used to treat rheumatoid arthritis
3. Compare differences in outcomes and extraarticular manifestations of rheumatoid arthritis in patients with seropositive and seronegative rheumatoid arthritis

#### MANAGING INFLAMMATORY BOWEL DISEASE IN THE ERA OF PERSONALIZED MEDICINE - Tim Zisman MD

1. Review natural history and complications of IBD and how they impact treatment approach.
2. Describe considerations in selecting therapy for patients with IBD
3. Discuss strategies to optimize short- and long-term response to medication in IBD

#### ROLE OF IR IN TREATMENT OF PROGRESSIVE PARKINSON'S DISEASE – Sanjiv Parikh MD

1. Describe treatment of Progressive Parkinson's Disease.
2. Describe Dopa Gel pump via dedicated Gastrojejunostomy tube
3. Discuss Efficacy of Dopa Gel

#### TARGETED THERAPIES IN NEUROLOGY - Leo Wang MD

1. Discuss Basic Pathology behind disease -
2. Describe Therapeutic development based on pathology
3. Analyze Cost and efficacy of treatment

#### MAKING A DIFFERENCE IN DIABETES: EVALUATING ETIOLOGY AND FACING FEARS AND FALSEHOODS - Janet Leung MD

1. Compare how risk factors for diabetes in South Asian populations differ from US (with majority Caucasian ethnicity)
2. Discuss when to consider evaluating for T1DM in adult onset diabetes, T2DM in childhood onset diabetes, and pancreatic (Type 3c) diabetes
3. Outline misconceptions patient (and their communities) have about T1DM and T2DM and how that can affect management

**PLANNING FOR THE WORST: CODE STATUS, POLST, AND ADVANCE CARE PLANNING - Hope Wechkin, MD**

1. Describe options for care in section B of the POLST form based on location of care.
2. Identify the survival-to-discharge rate of out-of-hospital cardiac arrest.
3. Identify a tool for advance care planning for patients with dementia.

**CASE OF HELLP SYNDROME - Sanjiv Parikh, MD**

1. Describe HELLP Syndrome – a catastrophic Pregnancy complication
2. Discuss Management of HELLP syndrome

**PERSONAL APPROACH TO HEALTHY LIVING - Happy Walia DDS**

1. Discuss Approach to healthy living
2. Discuss role of Alcohol for healthy living

**SLEEP HYGIENE - Ashish Trivedi MD**

1. Define good sleep hygiene
2. Outline current recommendation regarding the sleep duration.

Usha M Reddy

Usha M Reddy MD

Executive Director

Washington Association of Physicians of Indian Origin

Email: admin@wapiusa.com

Phone: 425 301-6317

*WAPI, an organization that is driven by the consensus of its members that has the following mission:*



*To provide an umbrella organization to bring together American Physicians, Dentists and Allied Healthcare Professionals of Indian Origin, defining Indian in the broad sense of Indian Ancestry; to provide a conduit to strive to be an exemplary strong ethnic group of professionals with a mission to serve the community by their expertise, cultural heritage and charitable work; to provide high educational and social services to its members. We envision this to be a collegial organization with actively participating members, who believe in its mission and are willing to further its cause.*